FDA Fast Track Designation for ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer
“These data represent an important clinical milestone for ETX-19477 and for the emerging field of PARG inhibition,” said Jeffrey A. Stafford, CEO of 858 Therapeutics. “We are encouraged by the clinical efficacy and RECIST responses observed to date, in both ovarian and breast cancer patients. These treatment outcomes, together with the robust PK-PD relationship established during dose escalation, support the continued development of ETX-19477, including combination approaches that can meaningfully expand the patient populations treatable with ETX-19477.”
Share:
More News
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “ADAURA continues to set new benchmarks in early-stage EGFR-mutated lung cancer, with nearly 80 per cent of patients treated with adjuvant Tagrisso alive at eight years. These results underscore the importance of treating early and reinforce Tagrisso as the adjuvant
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “DESTINY-Lung04 is the first Phase III trial to demonstrate superior progression-free survival versus the global first-line standard of care in patients with HER2-mutant advanced non-small cell lung cancer. These results add to the growing body of evidence supporting Enhertu as
“These regulatory clearances represent an important milestone for FL-261 and our strategy to expand targeted alpha therapy into various solid tumors,” said Debora Barton, MD, Chief Medical Officer of Full-Life Technologies. “[225Ac]Ac-FL-261 is designed to selectively target c-MET-expressing tumors by delivering potent alpha radiation directly into the tumor sites. We
“This financing, together with FDA clearance of the IND, marks an important inflection point for TwoStep and positions us to advance TS-104, our lead peptide-drug conjugate, through Phase 1 clinical development in oncology. This trial will provide the first clinical evaluation of the multi-specific targeting approach at the heart of